department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Contrave · pharmadog

pharmadog
drugs
Contrave

drug

patient view →

(bupropion hydrochloride + naltrexone) ER

Marketedupdated 2mo ago

by Currax Pharmaceuticals LLC

Approved

community read0 votes

indications

investigational

Obesity

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Contrave

generic

(bupropion hydrochloride + naltrexone)

indication

Obesity

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Jun 4, 2027

329 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

Jul 2, 2034method-of-use (U-1583)US 10231964
Jul 2, 2034method-of-use (U-1583)US 10828294
Jul 2, 2034method-of-use (U-1583)US 10835527
Jul 2, 2034method-of-use (U-1583)US 11998542
Jun 25, 2033method-of-use (U-1583)US 9633575
Jun 5, 2033method-of-use (U-1583)US 10403170
Jun 5, 2033method-of-use (U-1583)US 11139056
Jan 13, 2032method-of-use (U-1808)US 9248123
Jan 10, 2031method-of-use (U-1583)US 110335434.5y
Feb 2, 2030method-of-use (U-1639)US 89161953.6y
May 29, 2029method-of-use (U-1583)US 113247412.9y
Feb 3, 2029formulationUS 80887862.6y
Nov 8, 2027method-of-use (U-1585)US 103073761.3y
Nov 8, 2027method-of-use (U-1585)US 120487691.3y
Nov 8, 2027method-of-use (U-1584)US 83187881.3y
Nov 8, 2027method-of-use (U-1585)US 87220851.3y
Nov 8, 2027method-of-use (U-1585)US 91258681.3y
Jun 4, 2027method-of-use (U-1639)US 9107837329d

Data sources

ClinicalTrials.gov

last refreshed 57m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 8

tagApproval28 co-mentions · 14 sources
drugbupropion hydrochloride ER14 co-mentions · 14 sources
tagSmall Molecule14 co-mentions · 14 sources
drugAUVELITY14 co-mentions · 14 sources
drugbupropion14 co-mentions · 14 sources
drugbupropion hydrochloride MR14 co-mentions · 14 sources
drugbupropion hydrochloride SR14 co-mentions · 14 sources
drugWELLBUTRIN SR14 co-mentions · 14 sources

Trials studying (bupropion hydrochloride + naltrexone) ER

phase4Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesityrecruitingn=40
phase4Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.unknownn=89
phase4A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgeryunknownn=18